Big Pharma’s $15B Bet on a New Cancer Drug?

Heard the buzz? AstraZeneca might shell out up to $15 billion to get their hands on Summit’s new lung cancer drug, Ivonescimab. The catch: the drug helps patients go longer without their cancer getting worse, but it hasn’t proven it can help them live longer—yet. If you’re watching stocks, Summit’s price jumped while AstraZeneca’s dipped. For patients, this could mean more treatment options down the road, but the FDA still needs more proof before it hits the pharmacy shelves. #Business #Industry #HealthNews